BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Suven Life Sciences Ltd's PAT Up by 137% for 4th Quarter Ended 31st March 2012


5/4/2012 9:18:42 AM

HYDERABAD, INDIA (4 May 2012) – SUVEN LIFE Sciences Limited, a biopharmaceutical company specializing in drug discovery and developmental activities in Central Nervous System disorders, today announced its un-audited financial results for the quarter ended 31st Mar 2012. The un-audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 4th May, 2012 at Hyderabad.

Financial Highlights for the 4th Quarter ended March 2012:

Growth in revenue Rs 624 mil vs.Rs 465 mil - Up by 34.30%

Growth in PAT Rs 83 mil vs. Rs 35 mil - Up by 137.26%

Growth in EBIDTA Rs 130.23 mil vs. Rs 56.61 mil - Up by 130.07%

Suven’s major thrust on innovative R&D in Drug Discovery continues with a spending of Rs 84.5 mil (13.54% on revenue) for the quarter ended Mar’ 2012.

12 months period ended 31st Mar, 2012, recorded a revenue growth of 35.63%, increase in PAT by 49.26% and increase in EBIDTA by 70.272%. Total R&D expenditure for the year ended Mar’ 2012 stood at Rs. 332.82 mil (previous period Rs. 311.43 mil).

*PAT for the year ending Mar 2012 is after provision for MTM of Rs. 34.80 mil towards forward contracts due to exchange fluctuation

During the quarter there were major qualitative achievements with the grant of 3 product patents to Suven’s drug discovery pipeline which consists of 13 molecules out of which twelve (12) molecules currently in pre-clinical stage of development in addition to developmental candidate SUVN-502 for Alzheimer's disease and Schizophrenia.

For more information on Suven please visit our Web site at http://www.suven.com

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES